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ABSTRACT
Background
Nocturnal hypoglycemia frequently occurs in patients with type 1 diabetes mellitus (T1DM).
It can be fatal and is believed to promote the development of the hypoglycemia-unawareness
syndrome. Whether hypoglycemia normally provokes awakening from sleep in individuals who
do not have diabetes, and whether this awakening response is impaired in T1DM patients, is
unknown.
Methods and Findings
We tested two groups of 16 T1DM patients and 16 healthy control participants, respectively,
with comparable distributions of gender, age, and body mass index. In one night, a linear fall in
plasma glucose to nadir levels of 2.2 mmol/l was induced by infusing insulin over a 1-h period
starting as soon as polysomnographic recordings indicated that stage 2 sleep had been
reached. In another night (control), euglycemia was maintained.
Only one of the 16 T1DM patients, as compared to ten healthy control participants,
awakened upon hypoglycemia (p¼0.001). In the control nights, none of the study participants
in either of the two groups awakened during the corresponding time. Awakening during
hypoglycemia was associated with increased hormonal counterregulation. In all the study
participants (from both groups) who woke up, and in five of the study participants who did not
awaken (three T1DM patients and two healthy control participants), plasma epinephrine
concentration increased with hypoglycemia by at least 100% (p , 0.001). A temporal pattern
was revealed such that increases in epinephrine in all participants who awakened started
always before polysomnographic signs of wakefulness (mean 6 standard error of the mean: 7.5
6 1.6 min).
Conclusions
A fall in plasma glucose to 2.2 mmol/l provokes an awakening response in most healthy
control participants, but this response is impaired in T1DM patients. The counterregulatory
increase in plasma epinephrine that we observed to precede awakening suggests that
awakening forms part of a central nervous system response launched in parallel with hormonal
counterregulation. Failure to awaken increases the risk for T1DM patients to suffer prolonged
and potentially fatal hypoglycemia.
The Editors’ Summary of this article follows the references.
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Hypoglycemia is the limiting factor in the therapeutic
management of type 1 diabetes mellitus (T1DM) [1]. Each
year, about 25% of T1DM patients with intensive insulin
therapy experience at least one episode of severe hypo-
glycemia deﬁned by a hypoglycemic state requiring assis-
tance of another person [2,3]. It has been estimated that
about 55% of severe hypoglycemic episodes occur during
sleep [4]. Mild to moderate hypoglycemic episodes lasting
between 1 h and 12 h have been observed in 27%–56% of
monitored nights in T1DM patients [5–12]. Although these
episodes appear to be asymptomatic most of the time
[7,8,11], hypoglycemic episodes during sleep constitute a
particular problem in the management of T1DM, since even
a single hypoglycemic episode can reduce awareness of, and
neuroendocrine counterregulation against, subsequent hy-
poglycemia [13,14]. Hence, undetected hypoglycemic epi-
sodes during sleep may substantially contribute to the
development of a hypoglycemia-unawareness syndrome
frequently encountered in T1DM patients [15]. Moreover,
undetected nocturnal hypoglycemia has been considered to
be responsible for a large proportion of sudden deaths in
young T1DM patients, i.e., the dead-in-bed syndrome [16].
Such observations suggest that hypoglycemia does not
induce proper awakening in these patients, thereby pre-
venting an adequate behavioral control of this potentially
dangerous state. However, whether hypoglycemia normally
induces awakening in individuals who do not have diabetes,
but does not do so in T1DM patients, is at present unclear.
Jones et al. [17] have previously shown that neuroendocrine
counterregulation against hypoglycemia is impaired during
sleep in both T1DM patients and in healthy adolescents,
which could partly explain a tendency toward prolonged
nocturnal hypoglycemic episodes in the T1DM patients. In
healthy adults, sleep increased the glycemic threshold for
neuroendocrine counterregulatory responses, which means
that responses started at a lower plasma glucose level during
sleep than during wakefulness [18]. In this latter study, the
onset of the counterregulatory response coincided with a
transition to lighter sleep, with most healthy control
participants showing signs of awakening.
The effects of hypoglycemia on sleep in T1DM patients
have rarely been assessed systematically. Spontaneous hypo-
glycemia of variable extent in children with T1DM was found
to be associated with increased slow-wave sleep [19,20].
However, these studies leave open the question of whether
deepening of sleep is a cause or an effect of hypoglycemia.
There are also many clinical observations suggesting that
adult T1DM patients do not awaken during hypoglycemia
[11,12,21]. Hypoglycemia is more likely to cause seizures at
night than during daytime [22] and, in sleeping adult T1DM
patients, electroencephalogram abnormalities were identiﬁed
at an increased frequency during spontaneous hypoglycemic
episodes with blood glucose levels of less than 2.2 mmol/l
[5,23]. Such alterations point to a speciﬁc difﬁculty to awake
during a hypoglycemic state in these patients.
A recent study investigated T1DM patients and healthy
control participants during stepwise hypoglycemic clamps
performed in the late evening [24]. When the T1DM patients
were allowed to fall asleep after 2.5 h on the clamp, they
exhibited distinctly greater amounts of sleep than did the
healthy control participants during the subsequent 2.5 h on
the clamp, with this dissociation attaining signiﬁcance when
the lowest hypoglycemic level of 2.5 mmol/l was reached.
These data indicate an increased ability in T1DM patients to
fall asleep during a moderate hypoglycemia that was initiated
some time before sleep.
In the present study, we aimed to answer the question as to
whether hypoglycemia that emerges during ongoing sleep,
and the associated fall in blood glucose concentrations,
triggers a signal that, at a certain level, provokes awakening
from sleep in these patients. Awakening responses were
compared between T1DM patients and healthy control
participants. To elucidate whether awakening is a prereq-
uisite for a counterregulatory hormonal response, we also
examined whether awakening preceded or followed the
hormonal response to hypoglycemia.
Methods
Participants
We studied 16 T1DM patients (men/women: 9/7) and 16
healthy control participants (8/8) of comparable age (mean 6
standard error of the mean: 31.3 6 2.6 y and 28.4 6 1.5 y) and
body mass index (24.4 6 0.8 kg/m
2 and 23.0 6 0.6 kg/m
2).
Patients with T1DM were selected to participate only when
they had no clinical evidence of an autonomic neuropathy or
any other complication affecting patients with diabetes. Mean
diabetes duration in the patients was 9.1 6 1.4 y (range: 1–23
y). Mean HbA1c was 7.7% 6 0.3% (range: 6.0%–10.0%; upper
limit of the normal range: 6.8%). None of the T1DM patients
or control participants received any medication at the time of
the experiments except for insulin therapy in the T1DM
patients. Twelve patients were on an intensive conventional
therapy regime with at least three injections of regular insulin
and between one and two injections of long-acting insulin per
day. The remaining four T1DM patients were on continuous
subcutaneous insulin infusion. The mean 6 standard error of
the mean cumulative insulin dose was 55.8 6 3.8 U per day
(range: 37–82 U).
All T1DM patients measured their blood glucose concen-
tration at least four times per day. Eleven patients reported
regularly feeling hypoglycemic at threshold levels above 2.8
mmol/l, whereas the remaining ﬁve T1DM patients reported
noticing hypoglycemia only at levels of less than 2.8 mmol/l.
Based on this clinical criterion, these ﬁve patients were
classiﬁed as displaying an impaired awareness of hypoglyce-
mia. Only three of the 16 T1DM patients had reported
experiencing an episode of severe hypoglycemia within the
past year, i.e., being in a hypoglycemic state and requiring
assistance by another person. Nine patients reported having
had at least one such episode since being diagnosed with
diabetes.
The study conformed to the Declaration of Helsinki and
was approved by the Ethics Committee on Research Involving
Humans at the University of Luebeck. All study participants
gave written informed consent.
Experimental Protocol
Following an adaptation night in the laboratory, including
the placement of intravenous catheters and electrodes for
standard polysomnography, each patient with T1DM and
each control participant was tested during two experimental
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mia was induced by intravenous insulin infusion (hypogly-
cemic night). In the other night (control), euglycemic
conditions (.3.9 mmol/l) were maintained and plasma
glucose concentrations were measured hourly. Spontaneous
hypoglycemia was prevented by glucose infusion when
necessary—and this occurred in ﬁve of the T1DM patients’
control nights. The order of experimental conditions was
balanced across both the T1DM patients and the control
participants. In other words, eight T1DM patients and eight
healthy control participants started with the hypoglycemic
condition, while the remaining participants ﬁrst performed
the control condition. Within this scheme, each T1DM
patient and control participant was randomly allotted his or
her individual order. All T1DM patients and control
participants were informed that they could be subjected to
short periods of hypoglycemia during one night, but they
did not know whether and when this occurred. Thus,
experiments were performed in a single-blind fashion.
T1DM patients were instructed to inject their regular dose
of long-acting insulin before going to bed or to keep their
insulin pump at the regular infusion rate throughout the
night.
Procedure
On each experimental night, T1DM patients and control
participants reported to the laboratory at 2000 hours. Two
intravenous catheters were inserted in the distal part of the
right and left forearms for blood sampling and infusion of
insulin (Insuman Rapid, Aventis, http://www.sanoﬁ-aventis.
de). Electrodes were attached to the scalp (electroencephalo-
gram), around the eyes (horizontal and vertical electrooculo-
gram), and on the chin (electromyogram) for standard
polysomnography. Both groups of study participants went
to bed and lights were turned off at 2300 hours.
The polysomnographic recordings were monitored online
for signs of sleep. In the hypoglycemic night, insulin
infusion started at a continuous rate of 1.5 mU per kg of
body weight per min after the T1DM patient or control
participant had reached sleep stage 2 for the ﬁrst time and
had remained in this or a deeper sleep stage for 3 min.
Insulin was infused for about 60 min while plasma glucose
was measured at 5-min intervals using the Glucose Analyzer
II (Beckman Instruments, http://www.beckmancoulter.com).
Plasma glucose was allowed to fall in a linear manner such
that a target nadir level of 2.2 mmol/l was reached after ;60
min. To control the temporal dynamics of the decrease in
glucose concentration, a 20% glucose solution was infused
concurrently whenever necessary. At the nadir concentra-
tion of 2.2 mmol/l, insulin infusion was stopped and plasma
glucose levels were brought back into the normal range by
glucose infusion. A nadir level of 2.2 mmol/l was selected
based on available data which indicated that, at this level,
hypoglycemia can be safely induced without exposing the
T1DM patient or control participant to the risk of seizure or
any other major adverse events.
During the 60-min period of insulin infusion, blood
samples were collected every 5 min for determining counter-
regulatory hormone concentrations. Blood sampling and
infusions were carried out via long thin tubes (dead space:
1.5 ml) from an adjacent room without disturbing the
individual’s sleep. Samples used for analysis were collected
after drawing a buffer volume of about 5 ml.
Measurements
Polysomnographic recordings were scored ofﬂine accord-
ing to standard criteria [25] by two experts who were not
aware of whether the recordings were taken during the
hypoglycemia night or the control night. The following sleep
parameters were determined for the whole night: sleep
period time (time from sleep onset until ﬁnal awakening
deﬁned by the last occurrence of any sleep stage except
‘‘awake’’); total sleep time (time spent in sleep stages 1, 2, 3,
and 4, and rapid eye movement [REM] sleep between sleep
onset and ﬁnal awakening); time spent awake after sleep onset
in sleep stages 1, 2, 3, and 4; time spent in slow-wave sleep (i.e.,
sleep stages 3 and 4); REM sleep (in minutes and percentage
of sleep period time); and latency of the ﬁrst occurrence of
slow-wave sleep and REM sleep (with reference to sleep
onset). In addition, time spent in the different sleep stages
during the ﬁnal 10-min epoch of insulin infusion and during
the corresponding interval of the control nights was
determined in order to reveal acute effects of hypoglycemia.
The target variable of the study was the occurrence of
awakening during the hypoglycemic interval in T1DM
patients and control participants, as deﬁned by polysomno-
graphic criteria. Although clinically relevant, we did not
conﬁrm the individual’s awakening and responsiveness (e.g.,
by asking him/her if he/she is awake) in order not to interrupt
the experiment. The deﬁnition of wakefulness according to
standard polysomnographic criteria includes, amongst
others, brief muscle arousal, an increase in electromyo-
graphic activity, and a change to low-amplitude mixed-
frequency electroencephalogram activity with increased
proportions of alpha-waves (8–13 Hz) [25].
The following assays were used to measure counterregula-
tory hormonal responses. Plasma epinephrine and norepi-
nephrine were assessed using standard high-pressure liquid
chromatography; inter-assay coefﬁcient of variation (CV)
and intra-assay CV were, respectively, epinephrine ,5.6%
and ,2.9% and norepinephrine ,6.1% and ,2.6%. Plasma
ACTH was measured using luminescence immunoassay (Lu-
mitest,BrahmsDiagnostica,http://www.brahms.de), with inter-
assayCV,5.1%andintra-assayCV,3.2%.Serumcortisolwas
assessed using enzyme immunoassay (Enzymun-Test Cortisol,
Roche Diagnostics, http://www.roche.com), with inter-assay CV
,3.9% and intra-assay CV ,2.0%. Serum growth hormone
was measured using radioimmunoassay (HGH, Diagnostic
Products, http://www.dpcweb.com), with inter-assay CV
,3.4% and intra-assay CV ,1.6%. Plasma glucagon was
assessed using radioimmunoassay (Serono Diagnostics, http://
www.serono.com), with inter-assay CV ,6.1% and intra-assay
CV ,4.9%. Serum insulin concentrations were assessed using
ELISAs (Dako Cytomation, http://www.dako.com), with inter-
assay CV 7.5% and intra-assay CV 6.7%.
Statistical Analysis
Values are presented as mean 6 standard error of the
mean. Pairwise comparisons of the frequency of awakening
and of above-threshold counterregulatory hormonal re-
sponses between groups were based on chi-square tests.
Sleep data were analyzed by Student’s t-test and, where
appropriate, using nonparametric tests (Mann-Whitney U-
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were analyzed by analysis of variance (ANOVA) with the
repeated-measures factor ‘‘time’’ representing the repeated
hormonal assessments. For differences between T1DM
patients and control participants, a ‘‘group’’ factor was
included, with the ‘‘group 3 time’’ interaction term indicat-
ing different hormonal proﬁles over time. Note that since we
did not apply a formal adjustment of tests for multiple
comparisons (as such an adjustment did not appear to be
fully appropriate here), the statistical outcomes generally
should be interpreted with caution. Above-threshold coun-
terregulatory hormonal responses were deﬁned separately
for each hormone. Threshold levels for epinephrine, ACTH,
cortisol, and growth hormone were deﬁned as an increase of
100% with reference to the preceding 5-min interval.
Norepinephrine and glucagon threshold levels were deﬁned
by a respective increase of more than 50% within 5 min. The
choice of threshold criteria was based on previous studies
which proved that these criteria enabled identiﬁcation of an
emerging counterregulatory hormonal response during
stepwise hypoglycemic clamp experiments, unconfounded
by assay variability or by spontaneous hormonal ﬂuctuations.
The point in time at which levels exceeded the threshold for
the ﬁrst time was deﬁned as the onset of the respective
counterregulatory response. Degrees of freedom were
corrected according to the Greenhouse-Geisser procedure
where necessary. A p-value of less than 0.05 was considered
signiﬁcant.
Results
Plasma Glucose and Sleep Recordings
Before infusion of insulin, plasma glucose concentration
averaged 6.7 6 0.5 mmol/l in the T1DM patients and 5.8 6 0.3
mmol/l in the control participants (p ¼ 0.106). Serum insulin
levels were higher in the T1DM patients than in the control
participants (138 6 24 pmol/l versus 66 6 12 pmol/l; p ¼
0.012). During the insulin infusion, serum insulin levels
markedly increased but did not differ between the two
groups (1,110 6 162 pmol/l versus 1,014 6 120 pmol/l; p ¼
0.630). The insulin infusion started as soon as the T1DM
patient’s or control participant’s polysomnographic record-
ings indicated sleep stage 2 or deeper sleep for 3 min, which
was between 23:05 and 00:45 h. On average, infusion of
insulin started at 23:44 h in the T1DM patients and at 23:36 h
in the control participants. The following decrease in plasma
glucose concentration as well as its temporal characteristics
was similar between the groups (Figure 1). The nadir plasma
glucose concentration in the T1DM patients reached 2.22 6
0.01 mmol/l, and 2.24 6 0.02 mmol/l in the healthy control
participants (p ¼ 0.982).
During decreasing plasma glucose levels, ten of the 16
control participants showed clear-cut polysomnographic
signs of awakening, whereas this was the case in only one of
the 16 T1DM patients (p ¼ 0.001). During the corresponding
time interval (i.e., the hour after the ﬁrst occurrence of sleep
stage 2) in the control nights, in which no hypoglycemia was
induced, spontaneous awakening was not observed in any of
the T1DM patients or control participants. This result
indicates that the increased number of awakenings observed
during the hypoglycemia in the control participants reﬂects a
response to decreasing plasma glucose levels. The glucose
concentrations at which the ten control participants awak-
ened ranged between 2.2 and 2.7 mmol/l (mean 6 standard
error of the mean: 2.3 6 0.1 mmol/l). The one T1DM patient
who awakened did so at a concentration of 2.7 mmol/l.
Figure 2 illustrates representative time courses of poly-
somnographic sleep together with plasma glucose concen-
trations during infusion of insulin in different individuals. In
most T1DM patients or control participants who awoke
during hypoglycemia, this awakening occurred abruptly from
slow-wave sleep without a preceding period of more shallow
sleep.
The differential awakening response to hypoglycemia
between T1DM patients and healthy control participants
was conﬁrmed in an analysis of the sleep structure focusing
on the 10-min interval preceding the time of nadir glucose
concentration (summarized in Table 1). Mean proportion of
time awake during the 10 min before nadir glucose concen-
tration was 16% in the control participants and 3% in the
T1DM patients (p ¼ 0.005). Analyses of the total night, as
expected, revealed less total sleep in the hypoglycemic than in
the control nights. However, this difference was not
signiﬁcant, as the effects were diluted by the remaining hours
of uninterrupted sleep.
Counterregulatory Hormones
In parallel with the awakening response, an above-thresh-
old response of epinephrine (p¼0.005) and ACTH (p¼0.003)
to hypoglycemia was observed distinctly more often in the
control participants than in the T1DM patients (Table 2). As
Figure 1. Plasma Glucose Concentration during Insulin-Induced Hypo-
glycemia
Mean 6 standard error of the mean plasma glucose concentration in 16
control participants (open circles) and in 16 patients with T1DM (filled
circles) during insulin-induced hypoglycemia and the subsequent 30
min. Grey horizontal bars indicate intervals of wakefulness (determined
by polysomnography) in ten out of 16 healthy individuals awakening
upon hypoglycemia. The black horizontal line represents time awake for
the only T1DM patient who awoke during hypoglycemia. There were no
differences (p . 0.45) between T1DM patients and healthy control
participants in glucose infusion rates during the 1-h hypoglycemic
interval or between the study participants (from either group) who did
and did not wake up.
doi:10.1371/journal.pmed.0040069.g001
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hypoglycemia with strong increases in mean concentrations
of epinephrine (p ¼ 0.005, for the ANOVA time factor),
norepinephrine (p , 0.001), ACTH (p ¼ 0.009), cortisol (p ¼
0.015), and growth hormone (p ¼ 0.012). In contrast, in the
T1DM patients, these responses were weaker and not
signiﬁcant (p ¼ 0.278, p ¼ 0.367, p ¼ 0.166, p ¼ 0.572, and p ¼
0.740, respectively). ANOVA conﬁrmed differences in hor-
monal responses to hypoglycemia between the groups for
epinephrine (p , 0.001, for the ANOVA ‘‘group 3 time’’
interaction term), norepinephrine (p ¼ 0.006), ACTH (p ¼
0.037), and cortisol (p ¼ 0.001). The differences in the
Figure 2. Sleep, Plasma Glucose, and Epinephrine Concentrations in Five Individuals during Insulin-Induced Hypoglycemia
The panels depict time courses of polysomnographically recorded sleep (black line) in parallel with plasma glucose (green line) and epinephrine (red
line) concentrations during the 1-h insulin infusion (0 to 60 min).
(A and B) Data from two healthy control participants who displayed the typical awakening response to hypoglycemia.
(C) Data from a healthy control participant who did not awaken during hypoglycemia and remained in slow-wave sleep (sleep stages 3 and 4).
(D) Data from the only one of the 16 T1DM patients who awakened during hypoglycemia.
(E) Data from a typical T1DM patient who did not awaken during hypoglycemia.
Note that all study participants who woke up (A, B, and D) show marked rises in epinephrine levels that always start before awakening. Note also that
awakening occurred fairly abruptly in most cases (e.g., B and D), and was not preceded by a gradual lightening of sleep. (Left x-axis refers to sleep
stages—awake and sleep stages 1 to 4).
doi:10.1371/journal.pmed.0040069.g002
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signiﬁcant (p ¼ 0.084). Glucagon concentrations remained
unchanged by hypoglycemia in both healthy control partic-
ipants (p ¼ 0.153) and T1DM patients (p ¼ 0.842). Overall,
glucagon levels were lower in the T1DM patients than in the
control participants (p ¼ 0.025).
Comparison of T1DM Patients and Control Participants
with and without Awakening Response
Grouping study participants with respect to the presence
versus the absence of an awakening response to hypoglycemia
(across both the T1DM patients and the control participants)
revealed that awakening was associated with a strikingly
increased likelihood of an above-threshold response to
hypoglycemia in concentrations of epinephrine (p , 0.001),
ACTH (p , 0.001), and cortisol (p ¼ 0.005). However, an
increase in epinephrine levels during hypoglycemia was also
observed in ﬁve study participants (three T1DM patients and
two healthy control participants) who did not wake up,
indicating that an awakening response is not a prerequisite
for the activation of neuroendocrine counterregulation. On
the other hand, all T1DM patients and control participants
awakening upon hypoglycemia showed a clear-cut increase in
epinephrine levels, and this rise started in all cases before
polysomnographic signs of awakening occurred (on average
7.5 6 1.6 min; range: 2–17 min).
There were no differences in age (28.4 6 2.2 y versus 28.3
6 2.1 y; p ¼ 0.984) and body mass index (22.6 6 0.8 kg/m
2
versus 23.8 6 1.0 kg/m
2; p ¼ 0.359) between the healthy
control participants who did and who did not wake up. With
six out of eight men and four out of eight women showing an
awakening response (p ¼ 0.302), there was also no sign of a
possible inﬂuence of gender.
Discussion
Our data show that a decrease in plasma glucose concen-
tration to a nadir of 2.2 mmol/l within 1 h during sleep
induces a wake-up response in most healthy control
participants. In contrast, in T1DM patients, the identical
hypoglycemic stimulus very rarely causes awakening. The lack
of an awakening response was paralleled by an absence of
clear-cut counterregulatory hormonal responses to hypogly-
cemia in the great majority of T1DM patients.
Results from our healthy control participants provide
evidence that hypoglycemia belongs to the biological class of
stressors terminating sleep to allow adaptive behaviors such
as food intake. Awakening in the control participants
occurred at a plasma glucose level of less than 2.8 mmol/l
(range: 2.2–2.7 mmol/l) and, in all these cases, the wake state
persisted until glucose concentrations started to rise again.
Given the low glucose levels at which awakening occurred,
these ﬁndings agree with previous observations in healthy
adolescents as well as in T1DM patients who did not show
signs of awakening during a 40-min period of steady-state
hypoglycemia at concentrations of between 2.8 and 3.1 mmol/
l [17]. While the decrease in glucose was gradual, awakening
in our control participants mostly occurred somewhat
abruptly, not preceded by a transient period of lighter sleep.
Such a pattern strongly speaks for the existence of a discrete
glycemic threshold at which awakening regularly occurs. It
should be pointed out that, for ethical reasons, the
hypoglycemia induced in our study was only of short
duration, and plasma glucose levels were not allowed to fall
below 2.2 mmol/l. Assuming that in some individuals the
threshold is at an even lower concentration, this can explain
why not all of our control participants awoke around the time
Table 1. Sleep Parameters during the Final Ten Minutes Preceding the Nadir of Plasma Glucose on the Hypoglycemic Nights and
during the Corresponding Time Intervals on the Control Nights
Parameter Control Participants (n ¼ 16) T1DM Patients (n ¼ 16)
Control Night Hypoglycemic Night Control Night Hypoglycemic Night
Awake (%) 0 16 6 7
a 03 6 3
b
Sleep stage 1 (%) 7 6 41 2 6 47 6 21 4 6 3
Sleep stage 2 (%) 71 6 93 7 6 11 40 6 10
b 57 6 12
Slow-wave sleep (%) 17 6 83 5 6 11 52 6 12
b 26 6 11
REM sleep (%) 0.9 6 0.9 0 0 0
Movements (%) 14 6 53 0 6 71 6 6 51 3 6 4
b
Values are means 6 standard error of the mean. Sleep was assessed by standard polysomnography.
ap , 0.05, for comparison with control night in the same study participant group by paired Student’s t-test, except for wake time, where nonparametric Wilcoxon signed rank tests were
applied.
bp , 0.05 for comparison with respective night in the control participants by unpaired Student’s t-tests, except for wake time, where nonparametric Mann-Whitney U-tests were applied.
doi:10.1371/journal.pmed.0040069.t001
Table 2. Comparison of Awakening and Above-Threshold
Endocrine Responses to Nocturnal Hypoglycemia between
Healthy Control Participants and T1DM Patients
Response Control
Participants
(n ¼ 16)
T1DM
Patients
(n ¼ 16)
p-Value
Awakening (yes/no) 10/6 1/15 0.001
Epinephrine response (yes/no) 12/4 4/12 0.005
Norepinephrine response (yes/no) 9/7 3/13 0.127
ACTH response (yes/no) 10/6 2/14 0.003
Cortisol response (yes/no) 5/11 1/15 0.070
Growth hormone response (yes/no) 7/9 4/12 0.072
Data represent number of study participants. p-Values are derived from chi-square
testing.
doi:10.1371/journal.pmed.0040069.t002
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data indicate the presence of a glycemic threshold of
awakening that shows some variability among control
participants, but is below 2.8 mmol/l in most individuals.
Since our goal was to determine thresholds for awakening,
we induced hypoglycemia at a comparatively fast rate. This
approach diverges from many previous studies that inves-
tigated thresholds for counterregulatory hormonal responses
to hypoglycemia induced by a stepwise clamp procedure that
extends over several hours. This procedure has been
successfully applied to show that hypoglycemia (during a
stepwise clamp procedure that was already initiated before
sleep) leads to a general reduction in sleep efﬁciency [24].
However, the stepwise clamp procedure is less feasible for
determining thresholds of discrete awakening responses
because, with longer duration of hypoglycemic periods, there
is an increased probability of confounding inﬂuences from
spontaneous changes in sleep structure. Nevertheless, it
should be noted that the awakening threshold is likely to be
sensitive to rate effects so that, with a more gradual fall in
glucose, thresholds might even be at a lower glucose
concentration; however, this theory remains to be tested.
Inducing a short-lived hypoglycemia at a comparatively rapid
rate also prevents a straightforward comparison of the
counterregulatory hormonal responses obtained here with
those obtained in previous studies (e.g., [24]) that used slower,
stepwise hypoglycemic clamps allowing examination of the
fully developed counterregulatory response rather than—as
in this study—a mere decision about the presence or absence
of a hormonal response around the time of awakening. In
order not to disturb the study participant’s sleep by blood
sampling, we measured plasma glucose in venous rather than,
as in most previous studies, arterialized-venous blood. The
venous blood measurements of the present study, however,
provide higher glucose values than the measurements taken
in previous studies and further hamper direct comparisons
with those earlier studies.
It remains currently obscure as to what extent the
Figure 3. Counterregulatory Hormonal Responses during Insulin-Induced Hypoglycemia
Mean 6 standard error of the mean counterregulatory hormone concentrations during insulin-induced hypoglycemia in the 16 healthy control
participants (open circles) and in the 16 T1DM patients (filled circles).
doi:10.1371/journal.pmed.0040069.g003
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concurrent hyperinsulinemia. We did not perform hyper-
insulinemic-euglycemic clamps during control nights to
assess the effects of insulin during increased rates of glucose
infusion. However, although indirect, evidence from previous
studies using different modes of insulin and glucose admin-
istration does not point to any substantial effects of hyper-
insulinemia itself on sleep (e.g., [26,27]). Importantly, since
the rate of insulin infusion and the resulting hyperinsuline-
mia was identical in both T1DM patients and control
participants, this factor cannot explain the difference in
awakenings to hypoglycemia between the groups.
Since only one out of our 16 T1DM patients awoke during
hypoglycemia, this precludes any statistically based character-
ization of patients showing and not showing a defective
awakening response to hypoglycemia. Nevertheless, it should
be pointed out that the one T1DM patient who woke up upon
hypoglycemia, a 31-y-old woman (body mass index 21.1 kg/m
2;
Figure 2D), had the shortest diabetes duration (1 y). Thus, we
speculate that an impaired awakening response upon
hypoglycemia may develop with progressive duration of the
disease. It is also noteworthy that although this woman awoke
upon hypoglycemia, she exhibited several conditions that are
well known to increase the risk for a syndrome of
hypoglycemia unawareness—including counterregulatory
failure. Thus, she had a comparatively low HbA1c level of
6.7%, which is slightly below the upper limit of the normal
range (6.8%) and is also below the mean HbA1c level of the
group of T1DM patients studied (7.7 6 0.3%). In addition,
she had previously experienced one episode of severe
hypoglycemia (requiring a subcutaneous injection of gluca-
gon by another person). With regard to the unawareness
syndrome, our sample of T1DM patients overall was some-
what heterogeneous. Based on clinical criteria, ﬁve of the
patients indicated tendencies toward the presence of this
syndrome.
Awakening upon hypoglycemia was strongly associated
with the emergence of counterregulatory hormonal re-
sponses. Importantly, in all cases, the marked increase in
circulating epinephrine levels preceded the actual awakening,
on average by 7.5 min. The rise in epinephrine was distinctly
greater than that typically observed in conjunction with
regular awakening in the morning [28]. Moreover, in ﬁve of
the study participants (three T1DM patients and two healthy
control participants), the epinephrine response was not
followed by a polysomnographic wake state. This temporal
pattern excludes the possibility that attaining wakefulness is
essential for the emergence of a counterregulatory hormonal
response. Rather, awakening upon hypoglycemia forms part
of a central nervous system response that develops in parallel
with counterregulatory hormonal responses, and presumably
originates from hypothalamic inﬂuences on brainstem-
arousing structures [29]. This view does not exclude the
possibility that neuroendocrine and autonomic activity in
response to hypoglycemia can facilitate awakening [30],
although deﬁnitive conclusions on a causal relationship
between hormonal changes and awakening cannot be drawn
from our data.
Our results underscore an important, yet greatly neglected
problem in the management of T1DM. In response to
hypoglycemia, these patients do not only often fail to show
a hormonal counterregulatory response, but also often fail to
wake up when hypoglycemia develops during sleep. Lacking a
proper awakening response, these patients have only a
diminished chance to compensate behaviorally for sleep-
associated hypoglycemia by ingesting carbohydrates. In turn,
this leads to prolonged and aggravated nocturnal hypoglyce-
mic episodes. Considering the potentially harmful effects of
nocturnal hypoglycemia, which can even be fatal, restoring a
proper awakening response to hypoglycemia is a therapeutic
goal of utmost importance to these patients.
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Editors’ Summary
Background. Hypoglycemia (low blood sugar) is a frequent complica-
tion of insulin-treated diabetes, affecting patients with type 1 diabetes
mellitus in particular. In individuals who do not have diabetes, insulin
secretion is modified naturally and continuously by the body’s own
regulatory systems, depending on the blood sugar. However, in diabetes
patients there is a lack of natural insulin and so manufactured insulin has
to be given by injection after blood sugar testing. Hence, it is not
possible for patients with diabetes to modify insulin secretion naturally
in response to a change in glucose levels, and so blood glucose levels
can rise and fall beyond healthy levels. In individuals who have intensive
insulin therapy, hypoglycemia can be a particular problem; each year
about 25% of patients on intensive insulin therapy have at least one
episode of severe hypoglycemia—which requires the assistance of
another person.
When hypoglycemia occurs during the day, diabetes patients can
recognize it by a variety of symptoms, e.g., feeling sweaty and
lightheaded, and they may either seek help from another person or
treat themselves with sugar. Hypoglycemia during sleep may be very
common—it has been observed to occur in up to half of the nights when
patients with diabetes were monitored. The particular problem with
hypoglycemia occurring during sleep is that diabetes patients may not
be aware of it and hence may not be able to treat themselves or to seek
assistance. It is believed to contribute to some instances of sudden death
during sleep in patients with diabetes.
Why Was This Study Done? It has not been clear whether there is a
certain level of blood glucose below which a signal is triggered that
provokes awakening from sleep in either diabetes patients or in
individuals who do not have diabetes. The authors of this study wanted
to compare responses to lowered blood glucose in diabetes patients and
in individuals who do not have diabetes and to see whether the
responses differed. They also wanted to look at whether there were any
other hormonal changes that preceded or followed awakening after
hypoglycemia.
What Did the Researchers Do and Find? They treated two groups; 16
type 1 diabetes mellitus patients and 16 healthy control participants.
With careful monitoring, on one night once stage 2 sleep (as measured
by a method known as polysomnography) had been reached, they gave
insulin to lower the blood glucose to a specific level (2.2 mmol/l), which
would when awake give symptoms of hypoglycemia. On another night
(the control night) normal blood sugar levels were maintained.
They found that only one of the 16 diabetes patients, as compared to
ten healthy control participants, woke when hypoglycemia occurred. In
the control nights, none of the study participants in either of the two
groups awakened during the corresponding time. Awakening during
hypoglycemia was associated with substantial hormonal changes,
especially with an increase in one hormone, epinephrine (also known
as adrenaline), and the increases in this hormone occurred before
polysomnographic signs of wakefulness.
What Do These Findings Mean? It appears that patients with type 1
diabetes mellitus do not awake at a level of hypoglycemia that triggers
waking in normal individuals. The hormonal responses that were seen in
individuals who awoke may be part of a crucial response system to
hypoglycemia. These results help us to understand how diabetes
patients respond to hypoglycemia, but further work will need to be
done to determine whether it is possible to improve the response. It
should be noted, however, that the results are probably not general-
izable to patients with type 2 diabetes mellitus, who represent the
majority of patients with diabetes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040069.
  A related PLoS Medicine Perspective article by Ilan Gabriely and Harry
Shamoon discusses this study and more about hypoglycemia in T1DM
  MedlinePlus, the encyclopedia of health information from the US
National Library of Medicine, has a collection of pages on hypogly-
cemia
  Wikipedia pages on hypoglycemia (note that Wikipedia is a free online
encyclopedia that anyone can edit)
  National Diabetes Information Clearinghouse, a service of the US
National Institute of Diabetes and Digestive and Kidney Diseases, has
information on hypoglycemia
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